Ozempic, Wegovy prices to drop up to 50% as Novo Nordisk's rivalry with Eli Lilly heats up: report

Core Insights - Novo Nordisk plans to reduce list prices for its weight-loss and diabetes drugs Wegovy and Ozempic by up to 50%, with new prices set to be $675 per month starting January [1][3] - The price cut is a strategic move to regain market leadership from Eli Lilly, which has gained traction with its drugs Mounjaro and Zepbound [3] - This marks the first time Novo Nordisk has lowered its drug list prices, reflecting a significant shift in pricing strategy [3] Pricing Strategy - Wegovy and Ozempic will each be listed at $675 per month, representing a 50% reduction for Wegovy and a 34% decrease for Ozempic [1][7] - Novo Nordisk has also reduced cash prices for patients without insurance to a range of $149 to $499 per month, depending on the drug and dosage [7] - Eli Lilly has previously lowered the cash price of Zepbound to between $299 and $499 per month, down from over $1,000 [8] Market Dynamics - The number of Americans using weight-loss medications has more than doubled in the past year and a half, indicating strong demand [4] - Novo Nordisk aims to make these medications more accessible and affordable, particularly for patients enrolled in high-deductible insurance plans [4][5] - The global market for GLP-1 drugs is currently valued at approximately $72 billion and is projected to grow to $139 billion by 2030 [11] Competitive Landscape - The price cuts are part of a broader strategy to compete with Eli Lilly, which has been successful in the weight-loss drug market [3] - Both companies have been offering discounts to insurers and consumers to maintain competitive pricing [7] - Novo Nordisk is also launching a pill version of a GLP-1 for weight loss, expanding its product offerings [11]